Scarcity premium: the thing the company sells is becoming harder to get, and management is letting the shortage do the s
The model's full reasoning — Q3 2016 call → NOWe need to determine if management conveys that what the company sells is becoming harder for buyers to obtain, and that management is allowing that tightening to work in its favor. The transcript is about Fate Therapeutics, a biotech company developing cell therapies. The products are ProTmune, FATE-NK100, ToleraCyte, and iPSC-derived NK cells. The company is in clinical trials, not yet selling products commercially. So there is no "buyers" in the traditional sense. The question asks about "buyers" wanting what the company offers. In a biotech context, buyers could be patients, but more likely it's about the company's product availability. However, the company is not selling products yet; it's developing them. The transcript discusses clinical trial enrollment, regulatory designations, and progress. There is no mention of scarcity of product, capacity, or slots. The company is opening sites, enrolling patients, and advancing programs. There is no indication that availability is tightening. Management is not describing any shortage of their own output. They are working to advance clinical development. So the answer is NO. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LEGH · Q4 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly holding production levels steady to build backlog rather than ramping output, while continuing to hold pricing levels. Duncan Bates states: “We have held pricing levels and held production levels as we continue to build a backlog across the manufacturing plants” and later “we decided, hey, let's keep production where it is and keep building the backlog.
STM · Q3 2018 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management describing current shortages and a "stretched supply chain" for their own products (especially Automotive and Power Discrete), with backlogs confirming demand outrunning availability. They explicitly note pricing upside from the fractured supply situation in Power and treat the tightness as a positive dynamic rather than an urgent problem to fix.
ALL · Q3 2023 → YESThe question is: Does management convey that WHAT THE COMPANY SELLS IS BECOMING HARDER FOR BUYERS TO OBTAIN — availability tightening — AND that management is allowing that tightening to work in the c...YES The transcript shows management explicitly restricting new business growth in unprofitable states (California, New York, New Jersey down 75% in new applications) and describing this as part of the profit improvement plan that is working in their favor by improving margins and allowing selective removal of restrictions only where target returns are achieved.